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Abstract
Estimation of absolute risk of cardiovascular disease (CVD), preferably with population-spe-
cific risk charts, has become a cornerstoneof CVD primaryprevention. Regular recalibra-
tion of risk chartsmay be necessary due to decreasing CVD rates and CVD risk factor
levels. The SCORE risk charts for fatal CVD risk assessment were first calibrated for Ger-
many with 1998 risk factor level data and 1999 mortalitystatistics. We present an update of
these risk charts based on the SCOREmethodology including estimates of relative risks
fromSCORE, risk factor levels from the GermanHealth Interview and Examination Survey
for Adults 2008–11 (DEGS1) and official mortality statistics from 2012. Competing risks
methods were applied and estimates were independently validated. Updated risk charts
were calculated based on cholesterol, smoking, systolic blood pressure risk factor levels,
sex and 5-year age-groups. The absolute 10-year risk estimates of fatal CVD were lower
according to the updated risk charts compared to the first calibration for Germany. In a
nationwide sample of 3062 adults aged 40–65 years free of major CVD fromDEGS1, the
mean 10-year risk of fatal CVD estimated by the updated chartswas lower by 29% and the
estimated proportionof high risk people (10-year risk > = 5%) by 50% compared to the older
risk charts. This recalibration shows a need for regular updates of risk charts according to
changes in mortalityand risk factor levels in order to sustain the identification of people with
a high CVD risk.
PLOSONE | DOI:10.1371/journal.pone.0162188 September 9, 2016 1 / 11
a11111
OPENACCESS
Citation:Rücker V, Keil U, Fitzgerald AP, Malzahn U,
Prugger C, Ertl G, et al. (2016) Predicting 10-Year
Risk of Fatal Cardiovascular Disease in Germany: An
Update Based on the SCORE-Deutschland Risk
Charts. PLoS ONE 11(9): e0162188. doi:10.1371/
journal.pone.0162188
Editor: Chiara Lazzeri, AziendaOspedaliero
Universitaria Careggi, ITALY
Received:April 29, 2016
Accepted:August 18, 2016
Published:September 9, 2016
Copyright:© 2016 Rücker et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricteduse, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: The authors confirm
that some access restrictions apply to the data
underlying the findings. The informed consent given
by DEGS1 study participantsand by study
participantsof the cohorts forming the SCORE cohort
does not cover posting individual data in public
databases.However, DEGS 1 data are available upon
request by means of project agreements.Data
requests can be sent to the ElectronicData Center of
the Department of Epidemiologyand Health Reporting
of the Robert Koch Institute at EDS@rki.de.
Introduction
Current guidelines on prevention of cardiovascular disease (CVD) such as the European
Guidelines on cardiovascular disease prevention in clinical practice [1], recommend to guide
decisions to take preventive actions as well as the level of preventive actions (e.g. lifestyle rec-
ommendations, drug treatment) by an estimation of absolute risk of CVD based on multiple
cardiovascular risk factors [2, 3]. Since CVD prevention is not only an individual concern but
also a worldwide public health concern, there is a need for a common, albeit locally specific
risk assessment that can take account of regional disparities in CVD risk as well as of time
trends in CVDmortality and CVD risk factors.
As a result, the Third Joint Task Force of European and other Societies on Cardiovascular
Disease Prevention in Clinical Practice proposed in 2003 new CVD risk charts for Europe and
suggested the SCORE (Systematic COronary Risk Evaluation) project to estimate ten-year risk
of fatal cardiovascular disease [4, 5]. The SCORE charts were intended to be calibrated locally
which is an advantage compared to non-European based risk equations which considerably
overestimate absolute risk in European populations [6–8]. In the following years, risk charts
for high-risk and low-risk European countries have been issued and in addition national or
regional calibrations of the SCORE risk charts were performed in order to reflect specificmor-
tality and risk factor levels [4, 9–12]. These risk charts should be used for risk estimation in pri-
mary prevention only since patients with clinically manifest CVD are already considered as
high-risk individuals [1, 4]. In addition, risk can be higher than indicated in the risk charts in
patients with specific additional comorbidities (e.g. diabetes) as detailed in CVD prevention
guidelines. [1]. Accordingly, in 2005, a recalibrated SCORE-Deutschland risk chart was pub-
lished based on data for risk factor levels from the GermanNational Health Interview and
Examination Survey 1998 (GNHIES98) and the official national mortality statistics of 1999
from the Federal Statistical Office (Destatis) [13]. Since then, decreasing trends in major CVD
risk factors such as decreasing blood pressure and cholesterol levels [14, 15] and to a lesser
extent smoking prevalence [16] have been observed in Germany, as well as a marked decrease
in CVDmortality rates [17]. These trends suggested the need for an update of the risk charts
for Germany in order to avoid overestimation of risk and false positive categorization of people
from the general population into the high risk group.
Therefore, we updated the calibration of the risk charts based on the SCOREmethodology
for Germany using risk factor profiles from the most recent GermanNational Health Examina-
tion survey (DEGS1 study 2008–2011) as well as national CVDmortality rates in 2012. In
addition, risk estimates based on the risk charts published in 2005 and the updated ones were
compared in a representative sample of the general population in Germany.
Methods
Score project
The first SCORE risk charts for Europe were published in 2003 [4]. The SCORE Project pooled
data from 12 European prospective cohort studies from the years 1967–1991 including the
GermanMONICA-Augsburg cohort [18]. The SCORE dataset contains information from
205,178 persons (43% women and 57% men) representing 2.7 million person years of follow-
up and 7,934 documented cardiovascular deaths. Based on this dataset, risk charts for cardio-
vascularmortality were developed in 2003 predicting the absolute risk of dying from CVD in
the next ten years. The risk was modelled as a function of age, sex, systolic blood pressure
(SBP), cholesterol (total (TC) or total cholesterol/HDL-ratio (TC/HDL-C)) and smoking.
Two SCORE risk charts were developed, one for European populations at a high CVD risk
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(SCORE-high) and one for European populations at a low CVD risk (SCORE-low). For a more
precise prediction of risk estimates, calibration of the risk charts according to risk factor and
mortality levels of respective countries was proposed [4].
First calibration for Germany
The first calibration for Germany was published in 2005 [13]. The SCORE-Deutschland risk
charts were based on three terms: a German specific baseline absolute risk of death from CVD,
relative risks based on the estimates from the SCORE Project and estimates of average risk fac-
tor levels of SBP, cholesterol and smoking. The calculations of the SCORE-Deutschland risk
charts were based on a Cox proportional hazards model with age as a time variable with
delayed entry. Both TC and TC/HDL-C based SCORE-Deutschland risk charts were made
available. Previous analyses of the SCORE data had shown similar performance of the TC and
the TC/HDL-C based charts and risk estimation with any of the two versions had been recom-
mended in the first German SCORE calibration [13]. The calculations of the absolute risk for
the SCORE-Deutschland risk charts published in 2005 were calibrated using the officialmor-
tality rates of the year 1999 and risk factor data from the GNHIES98 [19, 20]; the relative risks
were derived from the SCORE dataset [4].
Updated calibration for Germany
For the updated calibration of 10-year risk of CVD based on the SCOREmethodology, recent
national estimates of age- and sex-specificmean levels of the risk factors SBP, smoking and
cholesterol (TC or TC/HDL-C) from the DEGS1 2008–2011 study were used. The investiga-
tions of the DEGS1 study were carried out in accordance with the Declaration of Helsinki,
including written informed consent of all participants. All study methods were approved by
the ethics committee of Charité–Universitätsmedizin Berlin and the federal data protection
and deral data protection and freedomof information authority. The examination sample of
DEGS1 included 7.115 participants aged 18–79 years from a Germany-wide two-stage clus-
tered sample from local population registries with standardizedmeasurements and interviews
[21]. TC and high density lipoprotein cholesterol (HDL-C) were measured using an enzymatic
assay (Architect ci8200, Abbott, Germany). Non-HDL-C was calculated by subtractingHDL-C
from TC. Three blood pressure (BP) measurements were taken at the right arm at 3-minute
intervals after a non-strenuous part of the examination and an additional 5-minute rest with
an automated oscillometricdevice (Datascope Accutorr Plus, Mahwah, NJ). Participants sat on
a height-adjustable chair, back supported, arm lying on a table at heart level, feet on the floor
and legs uncrossed. Three different cuff sizes were used. The second and third measurements
were averaged [14]. Smoking was defined as current self-reported smoking. In order to account
for the unequal sampling probabilities related to the sampling design and nonresponse, statisti-
cal analyses were weighted using a weighting factor [21] and the complex survey sampling was
taken into account using complex samples procedures in SPSS version 20.0 (SPSS Inc., Chi-
cago, Illinois, USA).
The updated calibration also used recent mortality data from Germany. Sex-stratified and
5-year age aggregated number of deaths from CVD and non-CVD (CVD: ICD-10 I10-I15,
I20-I25, I44-I51 and I61-I73) and the number of inhabitants from the year 2012 were collected
from officialmortality statistics.We used competing risk model that utilizes the cumulative
incidence function to calculate the average absolute risk of dying from CVD. The competing
risks model allows for the fact that there are competing causes of death that influence the
actual likelihoodof dying from CVD. Non-CVD death was considered as being the competing
event and death from CVD the event of interest. It was assumed that the relative risks of the
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respective risk factors didn’t change over the years. Therefore, relative risks for CVDmortality
were derived from an analysis of the entire SCORE database [4]. The statistical method for the
updated calibration is based on the methodology introduced previously [13] but was slightly
modified as follows: The calibration from 2005 interpolated the 5-year mortality rates to get
the average absolute risk of dying in the next ten years. In the new approach the 5-year mortal-
ity rates were held constant. No interpolation was used, because a linear interpolation disagrees
with the Markov assumption. Therefore, the estimates of age- and sex-specificmean levels of
the risk factors were evaluated with regression models using age in constant 5-year age groups
and not as a continuous variable. Thus, separate risk estimations for the 40–45 and for the 45–
49 year olds were provided in contrast to the 2005 calibration. As a sensitivity analysis, an inde-
pendent recalculation of the risk charts using the original approach was performed by one of
the authors who was blinded to the current recalibration analysis (APF). Statistical analyses
were performed in R 3.1.1. A detailed description of the recalibrationmethods is provided in
the Supporting information (S1 File).
Changes in 10-year risk of fatal CVD estimation
The change in estimated risk between the first SCORE-Deutschland risk charts published in
2005 and the updated risk charts presented in this paper has been evaluated by applying the
two risk charts to a nationwide sample of community-dwelling adults aged 40–65 years from
the DEGS1 study in 2008–2011 [21]. Out of 3,470 participants of the DEGS1 study aged 40 to
65 years, 131 (3.8%) were excluded due to missing data on major CVD (self-reported previous
diagnoses of coronary heart disease (CHD), stroke and heart failure) or missing data on vari-
ables included in SCORE. Of the remaining participants, 8.1% (men 10.9%, women 5.1%) were
excluded due to a history of major CVD, leaving a sample of 3,061 participants (unweighted
sample size) for estimation of cardiovascular risk (49.5% women, 50.5%men, mean age ± SD
50.9 ± 7.0 years). 10-year risks of fatal CVD were calculated using both the original and the
updated calibration methods. For higher precision, risk was directly calculated from the respec-
tive formulas not from risk chart readings. High risk was defined according to current guide-
lines as estimated 10-year risk of fatal CVD of 5% or more. Statistical analyses of DEGS1 data
were weighted as described above.
Results
The updated risk charts for estimation of the absolute 10-year- risk of fatal CVD in Germany
are presented in Figs 1 and 2. Two versions are shown, one using TC (Fig 1) and one using TC/
HDL-C (Fig 2). Both versions are stratified by sex and include age, smoking and SBP as addi-
tional risk factors. To estimate the absolute 10-year risk of CVD death for an individual, his or
her age needs to be rounded to the nearest age shown on the chart and the smoker or non-
smoker cell nearest to the person’s SBP and TC or TC/HDL-C ratio will provide the estimated
risk.
The updated charts consist of 480 cells. For comparison the cells of the age group 40–49
from 2005 were compared to the cells of age group 40–44 and to the ones of the age group 45–
49 from the updated risk chart. Compared to the 2005 predictions in the tables with TC, 34.2%
of the absolute cell predictions were higher and 5.6% were lower. For example, the highest
absolute risk displayed in a cell of the updated risk charts compared to the one published in
2005 decreased in the TC chart from 37% to 34% for men (absolute risk difference of 3) and
from 19% to 15% for women (absolute risk difference of 4) in the highest category for all risk
factors. The differences between the old and the updated risk chart for TC in corresponding
cells for the age categories 50–65 had a mean of 0.69% (SD +/- 0.72). For the tables with TC/
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HDL-C, 47.1% of the absolute risks estimated for Germany decreased in comparison with the
2005 risk chart [13] and the highest absolute risks displayed in a cell had a risk difference of 4
percentage points in the charts for men and 5 for women.
Since a slight adaptation in the calibration method was introduced compared to the first cal-
ibration of 2005 (use of constant vs. interpolated 5-year mortality rates), a sensitivity analysis
was conducted and the updated calibration was performed using both methods. This sensitivity
analysis showed an excellent agreement (intraclass correlation coefficient ICC = 0.99) between
the method used in the 2005 calibration and the present approach. Agreement was calculated
for the age range 50–65 years (320 cells) since for younger ages the cells do not directly
Fig 1. Updated (2015) risk charts for estimationof absolute 10-year risk (%) of fatal CVD in Germany based on the SCORE-Deutschland risk
charts (tableswith total cholesterol).
doi:10.1371/journal.pone.0162188.g001
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correspond (the first calibration has the age category 40–49, the updated calibration has the
two age categories 40–44 and 45–49). The differences between the two methods in correspond-
ing cells had a mean of 0.24% (SD +/- 0.27). The risk predictions using the method from 2005
were always slightly higher than the ones using the method from 2015. The method used in
2005 classified 3 additional cells (out of 320) as high risk compared to the method used in
2015.
When applied to a representative sample of the population living in Germany aged 40 to 65
years without a previous history of major CVD from the national health surveyDEGS1 2008–
2011, the updated risk charts using TC classified significantly fewer men and women as high-
Fig 2. Updated (2015) risk charts for estimation of absolute10-year risk (%) of fatal CVD in Germany based on the SCORE-Deutschland risk
charts (tableswith total cholesterol/HDL cholesterol ratio).
doi:10.1371/journal.pone.0162188.g002
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risk (10-year risk> = 5%) than the German 2005 charts (German risk charts published 2005:
5.2% [95% CI 4.3–6.1]; updated risk charts: 2.6% [95% CI 2.0–3.3]). Average risk was also sig-
nificantly lower in all age groups among men and women according to the updated charts
compared to the charts from 2005 (German risk charts published in 2005: 1.47% [95% CI
1.40–1.54]; updated risk charts 1.04% [95% CI 0.99–1.09]) (Fig 3).
Discussion
The SCORE risk charts for estimating the absolute 10-year risk of fatal CVD for the German
population from 2005 [4, 13] have been updated successfully based on the SCOREmethodol-
ogy [4]. More than a decade after the first calibration of the SCORE charts for Germany [13]
these updated charts reflect the decreasing trend in CVDmortality in Germany as well as
recent trends towards lower risk factor levels. As expected, the predicted absolute risk generally
decreased. The use of the calibrated charts from 2005 for Germany showed a substantially
higher population risk in a representative sample of the general population living in Germany
aged 40 to 65 years compared to the updated estimates.
Germany has seen a marked decline in cardiovascularmortality in the period between the
two risk chart calibrations. The calibration published in 2005 and the updated calibrations are
based on mortality data from 1998 and 2012 respectively, a period in which stroke mortality
declined by 51%, ischemic heart diseasemortality by 45% and overall CVDmortality by 36%
(www.gbe-bund.de;mortality rates per 100.000 inhabitants standardized to the population in
Germany 2011). In addition, there have been substantial changes in risk factor levels, as docu-
mented by the two national health surveys conducted in 1998 and 2008–2011. For example,
blood pressure declined considerably (both systolic and diastolic blood pressure by 5 mmHg)
[14]. Moreover, cholesterol levels [15] and the proportion of smokers in the German popula-
tion decreased slightly [16]. However, the fall in CVDmortality might only be partly explained
by the changes in risk factors as the chart predicts individual risk at specific risk factors levels
and, thus, we wouldn’t expectmajor changes in the risk chart if the observeddecrease in mor-
tality would be entirely explained by risk factor changes.
Numerous risk charts exist for estimating CVD risk. [22] In particular newer risk charts
acknowledge the need to issue risk charts for individual countries and recalibrate them regu-
larly [19]. The first recalibration of the risk charts for Germany based on the SCORE project
resulted in risk estimates that were between those of SCORE for high-risk and those of SCORE
for low-risk countries [13]. The updated risk charts presented in this paper make further
adjustments toward lower risk while still lying between SCORE-high and SCORE-low [4].
More than 40% of the 480 cells in the risk charts for Germany are higher and around 1% are
lower in comparison to the original SCORE-low risk chart cells [4]. In the updated risk charts
the age group 40–49 is divided into two age groups, 40–44 and 45–49 years. This allows for a
more precise prediction of the absolute risk. Predicted risk is generally lower according to the
updated risk charts compared to the first SCORE-Deutschland risk charts. However, due to
rounding of the predicted risk presented in the chart cells rounded predicted risk is numerically
the same in more than half of the cells.
Other risk charts are also used in Germany such as the PROCAM score [23], which is based
on an occupational cohort from the northwest of Germany, as well as charts like ARRIBA [24]
and CARRISMA [25], which are based on adaptations of Framingham risk scores. These
charts, however, do not take into account the recent declines in CVD and CVD risk factors in
Germany. Results of a German survey on the use of routine risk-scores among physicians
showed that more than 50% of the participating physicians believe that risk-scores for CVD
are useful for the successful prevention and treatment of CVD [26]. Therefore, it is important
Risk Chartsof Cardiovascular Disease in Germany
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Fig 3. Comparison of absolute10-year-risk of fatal CVD by age group in adults aged 40 to 65 years in Germany without
major CVD according to the first vs. the updated risk charts.
doi:10.1371/journal.pone.0162188.g003
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that a regular update of the risk-scores based on the current risk factor and mortality distribu-
tion of the general population is available.
Our study has certain strengths and limitations. Our recalibration has been confirmed by
independent recalculation. The strengths of risk charts based on the SCOREmethodology
include the large database of European cohorts and the simple and inexpensive use due to
restriction to only a few key risk factors. The original SCORE chart combined separate predic-
tions of CHD and stroke mortality.6 The method presented here is based directly on national
CVDmortality which allows for a more straightforward recalibration. This is of great impor-
tance since CVDmortality as well as risk factor levels have been changing considerably in the
last decades in many countries [17, 27]. However, two aspects of the SCORE-recalibrationmay
lead to an overestimation of the absolute CVD risk in the general population without preexist-
ing CVD. Ideally, calibration would not require national mortality statistics (which include
people with previous CVDwho have a higher 10-year-mortality risk than those without a pre-
vious CVD), but recent and regional data on mortality of a population free of CVD at baseline.
This could be approximated from national mortality statistics with recent and regional CVD
incidence data, which, however, are currently lacking. The second aspect is that the competing
risk principle is only applied to the country-specificbaseline risk but not in the Cox regression
to estimate the hazard ratios. This could be solved by using a Fine and Gray Model with com-
peting risks [28] in the 12 original cohorts of the SCORE Project, but is computationally chal-
lenging in the presence of left censoring and a model with age as time variable. Finally, it is a
general limitation of the SCORE charts that they are limited to fatal CVD prediction and to the
age range 40 to 65 years. However, the original SCORE data support robust risk estimation
only for fatal CVD and only in this age range. Risk prediction for higher age groups would only
be possible by adding cohort data in a higher age range as shown in a recent Norwegian exam-
ple [29].
Conclusion
The risk charts presented in this paper update the first SCORE-DeutschlandCVD risk charts,
based on the SCOREmethodology taking into account more than a decade of changes in
mortality and risk factor levels in Germany. The absolute ten-year risk of CVD in Germany
decreased substantially compared to the risk charts published in 2005. The updated charts
allowmore exact risk predictions and can help to improve CVD prevention on the population
level by a more precise identification of patients with a high risk of CVD.
Supporting Information
S1 File. Recalibrationmethods.
(DOCX)
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